Tony Coles has taken up the CEO role at Pfizer-spinout Cerevel Therapeutics. The appointment puts the man who led Onyx Pharmaceuticals to a $10 billion takeover in charge of using $350 million of Bain Capital’s money to advance a pipeline of neuroscience programs.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,